BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (November 2026)
14 slides from BeyondSpring's investor presentation, Nov 13, 2026
Slide 1: Turning the Tide in Cancer Therapy
Turning the Tide in Cancer Therapy Plinabulin - Redefining Oncology Efficacy and Tolerability November 2026 NASDAQ: BYSI Non-Confidential
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Company Highlights
Company Highlights Plinabulin: Durable Anti- DUBLIN-4: Confirmatory BYSI: Oncology- cancer Efficacy and Bone Global Phase 3 in Post-ICI focused Global Biotech Marrow Protection NSCLC, FDA Fast Track • Unique MoA • Company Overview GEF-H1–mediated dendritic-cell (DC) • Mechanism-based Population Foun
Slide 4: Plinabulin: Dual Immunomodulatory and Neutropenia-Mitigating Activity
Plinabulin: Dual Immunomodulatory and Neutropenia-Mitigating Activity Plinabulin releases GEF-H1 from microtubules, promoting dendritic-cell maturation and reducing CIN 1-6 Increase Chemotherapy DC Maturation & Tumor Vasculature Treatment Cycles & APC Activation Modulation Maintain Dose Intensity Re
Slide 5: DUBLIN-4 Targets a Large, Underserved Post-ICI NSCLC Population
DUBLIN-4 Targets a Large, Underserved Post-ICI NSCLC Population Despite strong first-line success, treatment options after progression remain limited ICI annual sales at ~$60 billion; Limited Treatment Options for Post- Projected NSCLC Patient Pool Post-ICI Unmet Need ICI NSCLC without Driver Altera
Slide 6: 12 Phase 3 Studies with No OS Benefit vs. Docetaxel in Post-ICI EGFR WT
12 Phase 3 Studies with No OS Benefit vs. Docetaxel in Post-ICI EGFR WT NSCLC Phase 3 study Patient Population Study Design median OS (M) OS HR P value Non-squamous SAPPHIRE 2/3L, non-squamous Sitravatinib (TKI) + Opdivo (PD-1) vs. docetaxel 12.2 vs. 10.6 p=0.144 HR=0.86 HR=0.98 Lenvima (TKI) + pemb
Slide 7: DUBLIN-3: Phase 3 Foundation for DUBLIN-4
DUBLIN-3: Phase 3 Foundation for DUBLIN-4 DUBLIN-3 Study: 2L/3L EGFR WT NSCLC after progression Established Safety Benefit on platinum therapy N=559 DP with significantly lower Grade 4 Neutropenia • All Cycles Day 8 - Day 8 is ANC nadir for docetaxel R Docetaxel (D) Docetaxel + Plinabulin (DP) Singl
Slide 8: Clinical Efficacy Supports DUBLIN-4 Plinabulin-Mechanism Patient Selection
Clinical Efficacy Supports DUBLIN-4 Plinabulin-Mechanism Patient Selection DUBLIN-3 efficacy in post-ICI subgroup signal and Study 303 prospective study data provide the clinical rationale for DUBLIN-4 in a Plinabulin-mechanism targeted population: • Non-squamous NSCLC + Progressed on ICI DUBLIN-3 P
Slide 9: DUBLIN-4 at a Glance: Confirmatory Global Phase 3 Study, FDA Fast Track Designation
DUBLIN-4 at a Glance: Confirmatory Global Phase 3 Study, FDA Fast Track Designation Docetaxel + Plinabulin vs. Docetaxel in Post-ICI, Driver-Negative Non-Squamous NSCLC N=442 Target Population Endpoints R Post-ICI Non-Squamous NSCLC Primary Double-Blind • Randomized • EGFR / ALK / ROS1 / RET WT 1:1
Slide 10: Plinabulin: One Drug, Multiple Clinical Pipelines
Plinabulin: One Drug, Multiple Clinical Pipelines 700+ patients treated with Plinabulin Indication/ Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name Target NSCLC Plinabulin + Docetaxel Study 103 (DUBLIN-3) (2nd/3rd line) Studies 105 & 106 Plinabulin alone or + CIN Prevention (PROT
Slide 11: Plinabulin: Clear Path to Value Creation in NSCLC & Beyond
Plinabulin: Clear Path to Value Creation in NSCLC & Beyond From Clinical Evidence to DUBLIN-4 and Commercial Potential + + DIFFERENTIATED ASSET PHASE 3 OPPORTUNITY VALUE CREATION Clinical & Safety Evidence DUBLIN-4 – MoA targeted Market & Commercial Path NSCLC post-ICI • Novel GEF-H1 mechanism • 442
Slide 12: Experienced Leadership and SAB Support to Drive Successful Clinical Execution
Experienced Leadership and SAB Support to Drive Successful Clinical Execution Min Qiu June Lu, PhD Na Li John Mao, PhD Helein Li, MD Hao Zhang Joy Jia Chief Executive Officer Chief Scientific Officer Chief Financial Officer SVP, Development VP, Clinical Science Senior Director, CMC VP, Finance Bioph
Slide 13: Complementary Board with Finance, Strategic and Business Excellence
Complementary Board with Finance, Strategic and Business Excellence Brendon Delaney Jen Majeti, PhD, MBA Lan Huang, PhD Mathew Kirkby, MA Patrick Fabbio Sihai Xu, MBA Director Vice Chairman Co-Founder & Chairman Director Director Director Seasoned commercial leader Biotech investor and Biotech entre
Slide 14: Thank You
Thank You General Inquiries: GENERAL@beyondspringpharma.com Investor: IR@beyondspringpharma.com Media: PR@beyondspringpharma.com www.beyondspringpharma.com